Oral SERD Camizestrant Prolongs PFS vs Fulvestrant in Breast Cancer

"The results of SERENA-2 support further development of camizestrant in ER-positive breast cancer."
MDedge News

source https://www.medscape.com/viewarticle/985507?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost